Modulation of the Brain Distribution of Imatinib and its Metabolites in Mice by Valspodar, Zosuquidar and Elacridar
- 413 Downloads
The selective protein tyrosine kinase inhibitor, imatinib, inhibits the growth of glioma cells in preclinical models, but its poor brain distribution limits its efficacy in patients. P-glycoprotein (P-gp, rodent Mdr1a/1b or Abcb1a/1b) and Breast cancer resistance protein (rodent Bcrp1 or Abcg2) were suggested to restrict the delivery of imatinib to the brain. This study evaluates the effect of administering selective inhibitors of these transporters together with imatinib on the systemic and cerebral disposition of imatinib in mice.
Materials and Methods
Wild-type, Mdr1a/1b(−/−) and Bcrp1(−/−) mice were given imatinib intravenously, either alone, or with valspodar, zosuquidar (P-gp inhibitors), or elacridar (a P-gp and Bcrp1 inhibitor). The blood and brain concentrations of [14C]imatinib and its radioactive metabolites were determined.
The blockade of P-gp by valspodar or zosuquidar (>3 mg/kg) enhanced the brain uptake of imatinib (∼4-fold) in wild-type mice, but not that of its metabolites. Blockade of both P-gp and Bcrp1 by elacridar (>3 mg/kg) produced significantly greater brain penetration of imatinib (9.3-fold) and its metabolites (2.8-fold). In contrast, only the lack of P-gp enhanced imatinib brain penetration (6.4-fold) in knockout mice. These results of brain uptake correlated reasonably well with those obtained previously by our group using in situ brain perfusion.
Imatinib and its metabolites penetrate into the brain poorly and their penetration is limited by P-gp and (probably) Bcrp1. Administering imatinib together with P-gp (and Bcrp1) transporter inhibitors such as elacridar may improve the delivery of imatinib to the brain, making it potentially more effective against malignant gliomas.
Key wordsbrain breast cancer resistance protein 1 imatinib metabolites P-glycoprotein
- BB ratio
Blood/brain concentration ratio
Breast cancer resistance protein
Central nervous system
Net transport coefficient
We thank Dr. Yves Auberson (Novartis Institutes for Biomedical Research) for providing zosuquidar and elacridar, Dr. Rachael Profit and Dr Owen Parkes for editing the English text. This work was supported by Novartis Pharma AG contract (Novartis-INSERM n° 03035A10) to Dr. Sébastien Bihorel and Dr. Jean-Michel Scherrmann.
- 3.R. Dagher, M. Cohen, G. Williams, M. Rothmann, J. Gobburu, G. Robbie, A. Rahman, G. Chen, A. Staten, D. Griebel, and R. Pazdur. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8:3034–3038 (2002).PubMedGoogle Scholar
- 4.T. Kilic, J. A. Alberta, P. R. Zdunek, M. Acar, P. Iannarelli, T. O’Reilly, E. Buchdunger, P. M. Black, and C. D. Stiles. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60:5143–5150 (2000).PubMedGoogle Scholar
- 5.E. Raymond, A. Brandes, A. Van Oosterom, C. Dittrich, P. Fumoleau, B. Coudert, C. Twelves, C. De Balincourt, D. Lacombe, and M. Van Den Bent. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC: NDDG/BTG Intergroup Study. ASCO Meeting Abstracts. 22:1501 (2004).Google Scholar
- 6.P. Y. Wen, W. K. Yung, K. Hess, S. Silbermann, M. Hayes, D. Schiff, F. Lieberman, T. F. Cloughesy, L. M. DeAngelis, S. M. Chang, L. Junck, H. A. Fine, K. Fink, H. I. Robins, J. J. Raizer, L. E. Abrey, M. P. Mehta, E. A. Maher, P. M. Black, J. Kuhn, R. Capdeville, R. S. Kaplan, A. Murgo, C. Stiles, and M. D. Prados. Phase I study of STI571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTC 99-08). Proc. Am. Soc. Clin. Oncol. 21: (2002).Google Scholar
- 8.P. Le Coutre, K. A. Kreuzer, S. Pursche, M. Bonin, T. Leopold, G. Baskaynak, B. Dorken, G. Ehninger, O. Ottmann, A. Jenke, M. Bornhauser, and E. Schleyer. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother. Pharmacol. 53:313–323 (2004).PubMedCrossRefGoogle Scholar
- 9.K. Neville, R. A. Parise, P. Thompson, A. Aleksic, M. J. Egorin, F. M. Balis, L. McGuffey, C. McCully, S. L. Berg, and S. M. Blaney. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin. Cancer Res. 10:2525–2529 (2004).PubMedCrossRefGoogle Scholar
- 10.D. A. Reardon, M. J. Egorin, J. A. Quinn, J. N. Rich, Sr., I. Gururangan, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, J. M. Provenzale, J. E. Herndon, J. M. Dowell, M. A. Badruddoja, R. E. McLendon, T. F. Lagattuta, K. P. Kicielinski, G. Dresemann, J. H. Sampson, A. H. Friedman, A. J. Salvado, and H. S. Friedman. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. 23:9359–9368 (2005).PubMedCrossRefGoogle Scholar
- 21.P. Breedveld, D. Pluim, G. Cipriani, P. Wielinga, O. van Tellingen, A. H. Schinkel, and J. H. Schellens. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65:2577–2582 (2005).PubMedCrossRefGoogle Scholar
- 22.Y. Takasato, S. I. Rapoport, and Q. R. Smith. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247:484–493 (1984).Google Scholar
- 24.Q. R. Smith, and J. M. Walker. A review of blood–brain barrier transport techniques. The blood–brain barrier—Biology and Research Protocols, Vol. 89, Humana, Totowa, NJ, 2003, pp. 193–208.Google Scholar
- 29.S. Desrayaud. Rôle de la glycoprotéine P dans la distribution cérébrale d’un dérivé de la cyclosporine, le SDZ PSC833, Université, René Descartes, Paris, France, 1997.Google Scholar
- 30.D. W. Everett, J. E. Foley, S. M. Singhvi, S. H. Weinstein, and S. J. Warrington. High-performance liquid chromatographic method for the radiometric determination of [14C] bucromarone in human plasma utilizing non-radiolabeled bucromarone as an internal standard. J. Chromatogr. 487:365–373 (1989).PubMedCrossRefGoogle Scholar
- 32.S. Cisternino, F. Bourasset, Y. Archimbaud, D. Semiond, G. Sanderink, and J. M. Scherrmann. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood–brain barrier in mice and rats. Br. J. Pharmacol. 138:1367–1375 (2003).PubMedCrossRefGoogle Scholar